Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA, Millipore Get US Clearance for Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merck KGaA's agreement to acquire Millipore has cleared US anti-trust review, Millipore said in a filing today with the US Securities and Exchange Commission.

The firms agreed to the deal at the end of February. Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion.

Millipore said in its SEC filing that the waiting period for a review by the US Department of Justice and the Federal Trade Commission had expired without a request for any additional information.

In early Wednesday afternoon trade on the New York Stock Exchange, shares of Millipore were up less than 1 percent at $106.22 per share.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.